Cellectis (CLLS) Net Cash Flow Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 198.34% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 467.41% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14,223.53% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 453.08% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -125.22% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 53.46% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -55.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.49% |
| Dec 31, 2025 | 157.69% |
| Sep 30, 2025 | -175.47% |
| Jun 30, 2025 | -377.39% |
| Mar 31, 2025 | -26.41% |
| Dec 31, 2024 | -119.31% |
| Sep 30, 2024 | 178.22% |
| Jun 30, 2024 | 2,538.29% |
| Mar 31, 2024 | -60.11% |
| Sep 30, 2023 | 48.34% |
| Jun 30, 2023 | 95.49% |
| Mar 31, 2023 | -316.52% |
| Sep 30, 2022 | 16.86% |
| Jun 30, 2022 | -154.64% |
| Mar 31, 2022 | 452.82% |
| Sep 30, 2021 | -438.77% |
| Jun 30, 2021 | 246.44% |
| Mar 31, 2021 | 97.75% |
| Dec 31, 2020 | -2.58% |
| Sep 30, 2020 | 86.23% |
| Jun 30, 2020 | -10.10% |
| Mar 31, 2020 | -74.15% |
| Dec 31, 2019 | 51.67% |
| Sep 30, 2019 | -1,033.84% |
| Jun 30, 2019 | -110.50% |
| Mar 31, 2019 | -65.09% |
| Dec 31, 2018 | -147.93% |
| Sep 30, 2018 | -82.30% |
| Jun 30, 2018 | 907.77% |
| Mar 31, 2018 | 9.47% |
| Dec 31, 2017 | -118.45% |
| Sep 30, 2017 | 353.44% |
| Jun 30, 2017 | -84.17% |
| Mar 31, 2017 | 84.80% |
| Dec 31, 2016 | 63.37% |
| Sep 30, 2016 | 236.87% |
| Jun 30, 2016 | -108.24% |
| Mar 31, 2016 | -2,744.58% |